Literature DB >> 19140688

Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4'-desmethoxyepisilvestrol.

Tim E Adams1, Mariana El Sous, Bill C Hawkins, Sebastian Hirner, Georgina Holloway, Mui Ling Khoo, David J Owen, G Paul Savage, Peter J Scammells, Mark A Rizzacasa.   

Abstract

Total synthesis of the anticancer 1,4-dioxane containing natural products silvestrol (1) and episilvestrol (2) is described by an approach based on the proposed biosynthesis of these novel compounds. The key steps included an oxidative rearrangement of the protected d-glucose derivative 11 to afford the 1,4-dioxane 12, which could be elaborated to the coupling partner 5 and a photochemical [3 + 2]-cycloadditon between the 3-hydroxyflavone 27 and methyl cinnamate followed by base-induced alpha-ketol rearrangement and reduction to give the cyclopentabenzofuran core 33. The core (-)-6 and 1,4-dioxane fragment 5 were united by a highly stereoselective Mitsunobu coupling with the modified azodicarboxylate DMEAD to afford the axial coupled product 36. Deprotection then gave episilvestrol (2). Silvestrol (1) was synthesized by a coupling between core (-)-6 and the dioxane 44 followed by deprotection. Compound 1 was also synthesized from episilvestrol (2) by a Mitsunobu inversion. In addition, the analogue 4'-desmethoxyepisilvestrol (46) was synthesized via the same route. It was found that 46 and episilvestrol 2 displayed an unexpected concentration-dependent chemical shift variation for the nonexchangeable dioxane protons. Synthetic compounds 1, 2, 38, 46, and 54 were tested against cancer cells lines, and it was found that the stereochemistry of the core was critical for activity. Synthetic analogue 4'-desmethoxyepisilvestrol (46) was also active against lung and colon cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140688     DOI: 10.1021/ja808402e

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  22 in total

1.  Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Authors:  Christina M Rodrigo; Regina Cencic; Stéphane P Roche; Jerry Pelletier; John A Porco
Journal:  J Med Chem       Date:  2011-12-19       Impact factor: 7.446

Review 2.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

3.  Total synthesis of (±)-rocaglamide via oxidation-initiated Nazarov cyclization.

Authors:  John A Malona; Kevin Cariou; William T Spencer; Alison J Frontier
Journal:  J Org Chem       Date:  2012-01-26       Impact factor: 4.354

4.  Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.

Authors:  U V R Vijaya Saradhi; Sneha V Gupta; Ming Chiu; Jiang Wang; Yonghua Ling; Zhongfa Liu; David J Newman; Joseph M Covey; A Douglas Kinghorn; Guido Marcucci; David M Lucas; Michael R Grever; Mitch A Phelps; Kenneth K Chan
Journal:  AAPS J       Date:  2011-04-16       Impact factor: 4.009

Review 5.  Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae).

Authors:  Sherif S Ebada; Neil Lajkiewicz; John A Porco; Min Li-Weber; Peter Proksch
Journal:  Prog Chem Org Nat Prod       Date:  2011

Review 6.  The relevance of higher plants in lead compound discovery programs.

Authors:  A Douglas Kinghorn; Li Pan; Joshua N Fletcher; Heebyung Chai
Journal:  J Nat Prod       Date:  2011-06-08       Impact factor: 4.050

7.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

8.  Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation.

Authors:  Stéphane P Roche; Regina Cencic; Jerry Pelletier; John A Porco
Journal:  Angew Chem Int Ed Engl       Date:  2010-09-03       Impact factor: 15.336

Review 9.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

10.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Authors:  Heather Sadlish; Gabriela Galicia-Vazquez; C Gregory Paris; Thomas Aust; Bhupinder Bhullar; Lena Chang; Stephen B Helliwell; Dominic Hoepfner; Britta Knapp; Ralph Riedl; Silvio Roggo; Sven Schuierer; Christian Studer; John A Porco; Jerry Pelletier; N Rao Movva
Journal:  ACS Chem Biol       Date:  2013-05-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.